Featured Interview- Richard Hollis of Hollis-Eden
Posted in Healthcare Stocks on November 17th, 2008This week at TWST, our special focus is on biotechnology.
As part of this, we’ve done an in-depth interview with Richard Hollis,
Chairman, President and CEO of Hollis-Eden Pharmaceuticals, Inc. (HEPH:NASDAQ) which gives special insight into this unique company.
Hollis-Eden Pharmaceuticals, Inc. is a world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. The company’s clinical drug development candidates include TRIOLEX™ (HE3286), a next-generation compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE™ (HE3235), a next-generation compound in a clinical trial for late-stage prostate cancer. In addition to these clinical development candidates, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases.
The full interview can be read at http://www.twst.com/pdf/aky614.pdf
ounced the selection of David W. Stevens as El Paso’s new CEO. Stevens has key experience in the business. According to a story by Joann S. Lublin in the
e, the company appointed Walter C. Rakowich, the current President and COO, the new CEO while lead trustee, Stephen L. Feinberg was slated to take over as chairman of the board. In addition to th
e major management changes the company also announced it would reduce general and administrative expenditures by 20 to 25%. The company further announced a reduction in its slated dividend. These key changes come after the company’s share price, according to a story by John Spence of 